anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Clinical decision-making for risk stratification for possible myocardial infarction (MI) uses high-sensitivity cardiac troponin (hs-cTn) thresholds that range from the limit of detection to several-fold higher than the upper reference limit (URL). To establish a minimum analytical variation standard, we can quantify the effect of variation on the population clinical measures of safety (sensitivity) and effectiveness [proportion below threshold, or positive predictive value (PPV)].
METHODS: From large datasets of patients investigated for possible MI with the Abbott hs-cTnI and Roche hs-cTnT assays, we synthesized datasets of 1 000 000 simulated patients. Troponin concentrations were randomly varied several times based on absolute deviations of 0.5 to 3 ng/L and relative changes of 2% to 20% around the low-risk threshold (5 ng/L) and URLs, respectively.
RESULTS: For both assays at the low-risk thresholds, there were negligible differences in sensitivity (<0.3%) with increasing analytical variation. The proportion of patients characterized as low risk reduced by 30% to 29% (Roche) and 53% to 44% (Abbott). At the URL, increasing analytical variation also did not change sensitivity; the PPV fell by less than 3%. For risk stratification, increased delta thresholds (change between serial troponin concentrations) increased sensitivity at the cost of a decreased percentage of patients below the delta threshold, with the largest changes at the greatest analytical variation.
CONCLUSIONS: At the low-risk threshold, analytical variation up to 3 ng/L minimally impacted the safety metric (sensitivity) but marginally reduced effectiveness. Similarly, at the URL even relative variation up to 25% minimally impacted safety metrics and effectiveness. Analytical variation for delta thresholds did not negatively impact sensitivity but decreased effectiveness.
PURPOSE:To obtain a sensor generating no stress-strain in a fine metal wire and showing no change in a resistance value even when annealing is performed, by connecting two or more fine metal wires inserting through a rod body at both end parts of the rod body in series. CONSTITUTION:A sensor is formed by covering a sensor element A with a cover B. A plurality of piercing holes 2... are provided to the rod body 1 of the element A by drilling and linear fine metal wires 3 are inserted through said holes. The fine wires 3 are connected at the leading end (a) and rear end (b) of the rod body 1 so as to stretch over the adjacent piercing holes 2, 2 and one resistance wire arranged in series is formed from the contact (c) exposed at the leading end (a) to a contact (d). The lead wires 5... inserted through the lead wire holes 4... piercing the vicinity of the center of the rod body 1 are respectively connected to the contacts c, d at every two. For example, a current source and a voltmeter are respectively connected to said wires 5... and voltage is measured while a current having proper magnitude is allowed to flow to the fine wires to measure the voltage value between the contacts (c), (d), that is, the resistance value of the fine wire 3 and the temp. change of the atmosphere of the sensor can be accurately determined.
The invention belongs to the field of traditional Chinese medicine, and particularly relates to a bone setting capsule for treating traumatic injuries. The bone setting capsule is pure Tibetan medicine and is to be taken orally. The bone setting capsule comprises pearl, alabaster, orthoclase, ruddle, gypsum rubrum, ash bark, and active ingredients, i.e. lindenleaf torricellia bark leaf, oxytropis reniformis, pseudo-ginseng and iguana that are processed. The preparation method comprises the steps of treating before feeding, processing, compounding, smashing, sterilizing, sieving, mixing, packing and warehousing. The bone setting capsule has functions of promoting blood circulation to remove blood stasis, reducing swelling, easing pain, and promoting reunion of fractured bones and the like. The bone setting capsule has an obvious pain relieving effect in treating the soft tissue injury, comminuted fracture, old injury, fracture of extremities, sudden sprain in the lumbar region, chest pain in the breathing process, extravasated blood coagulation, osteonecrosis at early and medium stages, vertebral compression fracture, osseous lesion, prolapse of lumbar intervertebral disc and the like, takes effect fast, is good in curative effect, short in treatment course, easy to use, safe and reliable, and has no side effect; the clinical effective percentage of the bone setting capsule is very high; and the bone setting capsule has a high reputation in Amdo of Tibetan and peripheral areas, and is well received by many people and patients.
INTRODUCTION: Cerebral small vessel disease (SVD) is a common cause of stroke/vascular dementia with few effective treatments. Neuroinflammation and increased blood-brain barrier (BBB) permeability may influence pathogenesis. In rodent models, minocycline reduced inflammation/BBB permeability. We determined whether minocycline had a similar effect in patients with SVD.
METHODS: MINERVA was a single-center, phase II, randomized, double-blind, placebo-controlled trial. Forty-four participants with moderate-to-severe SVD took minocycline or placebo for 3 months. Co-primary outcomes were microglial signal (determined using 11C-PK11195 positron emission tomography) and BBB permeability (using dynamic contrast-enhanced MRI).
RESULTS: Forty-four participants were recruited between September 2019 and June 2022. Minocycline had no effect on 11C-PK11195 binding (relative risk [RR] 1.01, 95% confidence interval [CI] 0.98-1.04), or BBB permeability (RR 0.97, 95% CI 0.91-1.03). Serum inflammatory markers were not affected.
DISCUSSION: 11C-PK11195 binding and increased BBB permeability are present in SVD; minocycline did not reduce either process. Whether these pathophysiological mechanisms are disease-causing remains unclear.
INTERNATIONAL CLINICAL TRIALS REGISTRY PORTAL IDENTIFIER: ISRCTN15483452 HIGHLIGHTS: We found focal areas of increased microglial signal and increased blood-brain barrier permeability in patients with small vessel disease. Minocycline treatment was not associated with a change in these processes measured using advanced neuroimaging. Blood-brain barrier permeability was dynamic but MRI-derived measurements correlated well with CSF/serum albumin ratio. Advanced neuroimaging is a feasible outcome measure for mechanistic clinical trials.
Combination antiretroviral therapy can offer patients potent suppression of HIV replication and improved immunologic functioning. However, despite aggressive antiretroviral regimens currently in use, only about 50 to 60 percent of patients attain plasma viral loads below 50 copies/ml after 24 weeks. Initiating treatment with a 4-drug regimen may increase this percentage, but this may also contribute to patient non-adherence, drug-related toxicities, potential cross-resistance to drugs used in future regimens, and high financial costs. Another strategy is early intensification (adding a single drug to an existing regimen) in patients who are at risk for attaining incomplete viral suppression after 24 weeks of therapy. ABC may produce a significant antiviral effect when used as an intensification agent in patients on a stable antiretroviral regimen. The results of this study will offer insight into the potential benefits of early treatment intensification.

Patients entering this study will have initiated potent antiretroviral therapy. Between 60 and 90 days \[AS PER AMENDMENT 1/9/01: 60 and 104 days\] after beginning their background regimen, patients are randomized to add either ABC (Arm A) or a matching placebo (Arm B) for 12 weeks. Patients completing 12 weeks of treatment continue on study for an additional 24 weeks to Week 36. Patients discontinue treatment if virologic failure occurs at any time. Patients still return to the clinic for HIV-1 RNA measurements at Weeks 12 and 36, depending on when discontinuation occurred. Patients who discontinue treatment at or after Week 12 due to virologic failure are offered open-label ABC for the remainder of the study (through Week 36). Blood samples are collected at Weeks 4, 8, 12, 20, 28, and 36. Plasma samples for population sequencing of HIV-1 PR and RT genes are collected on all patients at study entry and at the time of virologic failure. Baseline genotype (presence or absence of PR and RT resistance mutations and number of resistance mutations) is correlated to treatment outcome. Samples from the time of failure are analyzed for the accumulation of additional resistance mutations. \[AS PER AMENDMENT 5/5/00: Patients and their primary care physicians will be unblinded to the patient's treatment after the study is completed at Week 36 or if virologic failure occurs at or after Week 12 \[AS PER AMENDMENT 1/9/01: or if ABC hypersensitivity is suspected\].\]
PURPOSE: To obtain a compsn. which contains a potassium route activator or a mixture of the activator and anti-inflammatory drug as an effective component which can be used to cure inflammatory symptoms without causing gastrointestinal ulcer and is effective to prevent or cure gastrointestinal ulcer symptoms of mammals. CONSTITUTION: This compsn. to prevent or cure gastrointestinal ulcer symptoms is obtd. by compounding (A) a single potassium route activator comprising a well-known compd. as Nicorandile. Minoxidil, Pinacidil expressed by formula I, Cromakealim expressed by formula II and a compd. expressed by formula III, or by compounding (A) and (B) an anti-inflamatory drug (such as acetylsalicylic acid). In formula III, a, b, c are all C or one is N or NO and another two are C, R1 is expressed by formula IV, wherein R7 , R8 are each bonded with N to represent 1-pyrolidinyl, 1-pipelidinyl group, etc., R9 is H, alkyl or aryl group, R2 is H, OH, acetyloxy, R3 , R4 are each bonded with C to represent 5 to 7-member carbon cyclic group, R5 is H, alkyl, etc., and R6 is H, OH, alkyl, etc.
Interferential current will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
Shoulder pain is the most common complication in hemiplegia after Stroke (CVA). Almost three quarters of all patients with hemiplegia will suffer from shoulder pain in the first twelve months after stroke. Because of the lack of effective treatment today, the optimal management of hemiplegic shoulder pain is prevention. Although widely studied, all clinical trials for shoulder pain in stroke fail to show efficacy. TF was never investigated to treat Hemiplegic Shoulder Pain (HSP). The investigators hypothesize that injecting the epidural space at the C6 level via transforaminal would desensitize both central medullary components of pain as peripheral sensitized structures such as the suprascapular nerve of the affected shoulder.

To test this hypothesis, the investigators developed a treatment protocol consisting of two C6 transforaminal epidural steroid injection with dexamethasone (TF with 0.5mL of lidocaine 1% and 1.5mL of Dexamethasone 10mg/ml). This procedure was compared to a sham intervention.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to oncology and can be used for optimisation of Hodgkin's lymphoma of IIIA stage treatment in adults. Method is realised in the following way. In case there are no symptoms of intoxication, patients with histological subtype nodular sclerosis and with histological grade at which 75% and more of cellular nodules contain only dispersed Berezovsky-Stenberg cells located on rich in lymphocytes mixed cellular or fibrohistiocytic background, 2-3 cycles of introductory combined chemical therapy are carried out according to schemes MOPP, MOPPABV or ABVD. After that total or subtotal irradiation of lymphatic nodules is performed. ^ EFFECT: application of invention allows to determine indications for chemical-radiological therapy taking into account versions of histological structure of tumour, ensures long-term recurrence-free survival rate and reduces treatment toxicity. ^ 2 ex
The project will be a prospective trial involving patients consented for a clinically indicated atrial fibrillation (AF) ablation using FIRM mapping. The purpose of the study is to collect additional information before, during, and after the ablation procedure. All patients will undergo a contrast-enhance MRI scanning with gadolinium-based contrast agent prior to the procedure as it provides a 3-dimensional image of both the left atria and right atria. The primary endpoint of this study will be the presence or absence of a correlation between micro-anatomic fibrotic tracks, determined by a combination of atrial wall thickness, and local scar and fibrosis, and sites of FIRM map indicated rotor activity. Medical information will also be collected after the patients 2nd, 3rd and 6 month standard of care doctor visits. There are no additional risks associated with this protocol over and above that of the standard risk of atrial fibrillation ablation with FIRM, and those associated with the standard risk of magnetic resonance imaging with gadolinium contrast agent, but there is a small risk of the loss of confidentiality when participating in an observational study. The potential benefits includes the possibility of greater understanding of the patient's specific disease state.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to experimental oncology. Anesthesia is introduced in immunodeficient mice. Skin and abdominal walls are dissected in layers. Abdominal wall is incised along the midline of the body, the beginning of the incision is located at distance of 20 mm from the end of the xiphoid process, the end of incision is 5 mm from the urethra. Cecum is removed into the surgical wound. At distance of 5 mm from an extreme point of the end part of the cecum, a serous-muscular suture is applied without tightening the threads. Serous-muscular layer 3 mm long is dissected in an end portion of the cecum. Invagination of an end part of the cecum is performed, thereby forming a pocket into which 27 mmtumor fragment of the human colon is immersed. Ligature is tightened. Cecum is immersed into an abdominal cavity. Wall of the abdominal cavity is closed in layers.EFFECT: method enables to obtain an orthotopic patient-like colon cancer model which most adequately reflects the characteristics of human colorectal cancer and is a valuable tool for preclinical studies of various methods of treating colon cancer, including for research of efficiency of new pharmacological substances, and also provides high potential of acceptance of tumor material.1 cl, 6 dwg, 1 ex
A water swellable cross-linked polyacrylate elastomer comprising at least one phosphate or phosphonate moiety and method of preparation is provided. The elastomer can advantageously be included in skin treatment compositions. Swellable elastomers in accordance with the invention are particularly well suited for inclusion in skin tightening cosmetic products. The elastomers can be formulated to form a film. When applied to skin, an elastomer in accordance with preferred embodiments of the invention can adhere to the skin and shrink as it dries. This can provide a skin tightening, lifting and wrinkle smoothening effect upon drying. This effect can temporarily mask the appearance of wrinkles. The elastomer may be the reaction product of reaction components comprising an acrylate or methacrylate moiety-containing component having 3 to 60 carbon atoms and a phosphate or phosphonate moiety-containing component having 3 to 60 carbon atoms. The reaction components may further comprise a siloxane component.
Testosterone Topical Gel, 1.62% Metered Pump. One actuation of 20.25 mg.
<P>PROBLEM TO BE SOLVED: To update incidental information incidental to a medical image to new information and to reflect the update on an image server when referring to the medical image in an image viewer terminal.  <P>SOLUTION: A diagnostic reading terminal 40 transmits an order relating information acquisition request to an RIS 10, and acquires order relating information from the RIS 10. Also, the diagnostic reading terminal 40 transmits a DICOM image data acquisition request to an image server 30 and acquires DICOM image data from the image server 30. Then, the diagnostic reading terminal 40 determines the presence/absence of consistency between patient information and/or inspection information included in the order relating information and patient information and/or inspection information included in the DICOM image data. Then, the diagnostic reading terminal 40 corrects the inconsistent incidental information of the DICOM image data and transmits the DICOM image data to the image server 30.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Participants who were receiving raltegravir (RAL) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
There are several types of periodontal and peri-implant soft tissue defects that require surgical treatment to reestablishment function and aesthetics. Therefore, surgical procedures for the reconstruction of the gingival and peri-implant tissues are routinely performed. However, these procedures do not always have predictable outcomes, and problems with the wound healing process can occur, which can impair the outcomes. To overcome this problem, new materials, drugs, and devices have been used to improve the results of surgical procedures. The present study is a controlled clinical trial that will include seventy-five patients with an indication of anterior maxillary tooth extraction for ridge preservation. The ridge preservation will be performed and a free gingival graft harvest from the palatal mucosa will be used to seal the socket entrance. Thereafter, the palatal wound will be randomly assigned into 3 groups: Control Group (C; n=25): open wound on palatal mucosa that will receive no treatment. Blank Film Group (BF; n=25): open wound on palatal mucosa that will receive silk fibroin film as dressing. Insulin-loaded film (IF; n=25): open wound on palatal mucosa that will receive an insulin-loaded silk fibroin film as a delivery system. Clinical, immunological, histological, and microbiome parameters will be analyzed.
Patients receive androgen receptor antagonist ARN-509 PO daily for 3 months. Patients then undergo radical prostatectomy.
Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises. a combination of all these types of exercises will be used. Repeat these exercises 5 times, with 3 repetitions done each day for four consecutive weeks.
In 1958, the presence of citrulline in the structure of the proteins was discovered for the first time. Several years later they found that Arginine converted to citrulline during a post-translational modification process by PAD enzyme. Each PAD is expressed in a certain tissue developing a series of diseases such as inflammation and cancers. Among these, PAD2 and PAD4 play a role in the development of rheumatoid arthritis (RA) by producing citrullinated autoantigens and increasing the production of inflammatory cytokines. PAD4 is also associated with the formation of NET structures and thrombosis. In the crystallographic structure, PAD has several calcium binding sites, and the active site of the enzyme consists of different amino acids. Various PAD inhibitors have been developed divided into pan-PAD and selective PAD inhibitors. F-amidine, Cl-amidine, and BB-Cl-amidine are some of pan-PAD inhibitors. AFM-30a and JBI589 are selective for PAD2 and PAD4, respectively. There is a need to evaluate the effectiveness of existing inhibitors more accurately in the coming years, as well as design and production of novel inhibitors targeting highly specific isoforms.
Methods and compositions are provided for the treatment of Parkinson's Disease. Aspects of the methods include administering Miro1 reducer. Also provided are reagents and kits for practicing the subject methods. In some embodiments, a method is provided for reducing undesirable levels of Miro1 in a cell having depolarized or otherwise damaged mitochondria. In some embodiments the cell is in vivo, e.g. in an animal model for PD, in an individual diagnosed with PD, in a clinical trial for treatment of PD, and the like.
Lymph node (LN) status is an essential prognostic factor in breast cancer (BC) patients, with an important role in the surgical and therapeutic plan. Recently, we have been developed a novel system for real-time intra-operative electrical LN scanning in BC patients. The ELS scores were calibrated by pathological evaluation of the LNs. Herein, we evaluated the efficacy of ELS in a prospective study for non-chemo-treated breast cancer patients. This is a prospective study in which ELS scores are blind for pathologists who declare the clearance or involvement of LNs based on permanent pathology as the gold standard. ELS and frozen-section (FS) pathology results were achieved intra-operatively, and samples were sent for the permanent pathology. The score of ELS did not affect the surgeons' decision, and the treatment approach was carried out based on FS pathology and pre-surgical data, such as imaging and probable biopsies. Patients were recruited from October 2021 through November 2022, and 381 lymph nodes of 97 patients were included in the study. In this study we recruited 38 patients (39.2%) with sentinel lymph node biopsy (SLNB) and 59 patients (60.8%) with ALND. Of the 381 LNs scored by ELS, 329 sentinel LNs underwent routine pathology, while others (n = 52) underwent both FS and permanent pathology. ELS showed a sensitivity of 91.4% for node-positive patients, decreasing to 84.8% when considering all LNs. Using ROC analysis, ELS diagnosis showed a significant AUC of 0.878 in relation to the permanent pathology gold standard. Comparison of ELS diagnosis for different tumor types and LN sizes demonstrated no significant differences, while increasing LN size correlated with enhanced ELS sensitivity. This study confirmed ELS's efficacy in real-time lymph node detection among non-chemo-treated breast cancer patients. The use of ELS's pathological scoring for intra-operative LN diagnosis, especially in the absence of FS pathology or for non-sentinel LN involvement, could improve prognosis and reduce complications by minimizing unnecessary dissection.